Updated Results On Heart Assist Device Presented At International Transplant Meeting

April 23, 1999

Includes Data Submitted For FDA Approval Of Novacor® System

SAN FRANCISCO, April 23 -- Results of a study of more than 150 patients sustained on the Novacor® Left Ventricular Assist System (LVAS) as a "bridge" to transplantation were presented for the first time at the International Society for Heart and Lung Transplantation (ISHLT) annual meeting today. The findings, which represent experiences of 22 U.S. transplant centers, included data that served as the basis for U.S. Food and Drug Administration (FDA) approval of the system less than a year ago. The Novacor LVAS is a product of the Cardiovascular Group of Baxter Healthcare Corporation.

Those patients who were discharged from the hospital with the Novacor LVAS while waiting for donor hearts fared better than patients whose medical condition required them to stay in the hospital, reported Robert Kormos, M.D., associate professor of surgery and director of the artificial heart and adult transplantation program at the University of Pittsburgh Medical Center (UPMC). About a third of the patients (29 percent) waited outside the hospital, six for more than a year and two for more than two years, allowing them the opportunity to lead normal, productive lives.

"The clinical experience with the discharged patients indicates there is improved quality of life and highlights the safety and feasibility for long-term use," said Dr. Kormos, a principal investigator of the multi-center trial.

With the number of patients being placed on transplant waiting lists growing each year but the supply of available organs remaining relatively stagnant, artificial assist devices serve a critical function by providing patients a means to sustain heart function until human donor hearts can be found. There are currently more than 4,200 patients on the national heart transplant waiting list, according to the United Network for Organ Sharing, and waiting times can exceed two or three years in some parts of the country. About 20 percent of those waiting die each year; last year, more than 760 died waiting for hearts.

"Assist devices have literally saved patients' lives who could have easily been counted as another death statistic. And unless we are able to produce enough organs to meet the supply, we will need to depend more and more on this type of technology," commented Dr. Kormos, who is also president-elect of the ISHLT.

The FDA approved the Novacor LVAS in September 1998, but the results presented by Dr. Kormos today had not previously been presented or published.

Between 1996 and 1998, 156 patients were placed on the Novacor LVAS, an electromagnetically driven pump surgically implanted in the abdomen that connects to the heart's main pumping chamber, the left ventricle. An electronic controller and battery pack worn on a belt or as a shoulder bag provide power. Their outcomes were compared to a group of 35 control patients who were treated with conventional medical therapy.

Of the 156 patients, 129 met all study entry criteria. Of the LVAS patients, 77 percent were successfully transplanted, compared to 37 percent of the control group. Deaths on the waiting list were fewer for those on the Novacor LVAS, 23 percent compared to 63 percent for those patients not placed on an assist system, reported Dr. Kormos.

Fourteen patients in the study remain on the device still waiting for heart transplantation. The average time on the device was 97 days; one patient has remained on the device now for nearly 1,000 days.

The Novacor LVAS provides circulatory support by taking over most of the workload of the failing heart. An inflow circuit directs blood from the left ventricle into the blood pump, and the pump ejects blood through an outflow conduit into the body's arterial system.

The wearable controller and batteries are connected to the implanted pump by a small tube containing several wires through the patient's skin. The system is self-regulating, responding instantaneously to a patient's changing heartbeat and circulatory demands.

UPMC has gained some of the most extensive experience using the Novacor LVAS as well as other assist systems. In addition to its active clinical program, UPMC also performs basic and animal research of various devices at its McGowan Center for Artificial Organ Development.
-end-


University of Pittsburgh Medical Center

Related Transplantation Articles from Brightsurf:

A revolutionary new treatment alternative to corneal transplantation
A new approach in ophthalmology that offers a revolutionary alternative to corneal transplantation has just been developed by researchers and clinicians in North America, Europe, and Oceania.

Fewer complications after organ transplantation
A large international study coordinated by University Hospital Regensburg and Charité - Universitätsmedizin Berlin has demonstrated the safety of new cell therapy approaches for use in kidney transplant recipients.

Elderly patients also benefit from kidney transplantation
So far, kidney transplantation has generally not been offered to elderly patients (>75 years) because of the perioperative risks.

New material will allow abandoning bone marrow transplantation
Scientists from the National University of Science and Technology 'MISIS' developed nanomaterial, which will be able to restore the internal structure of bones damaged due to osteoporosis and osteomyelitis.

Fewer medical tests -- timely listing for transplantation
Younger patients would benefit greatly from kidney transplantation. Their expected remaining lifetime may even be doubled by having a transplant.

Uterus transplantation -- ethically just as problematic as altruistic surrogacy
In 2014, the first child to have been gestated in a donated uterus was born.

Advancing transplantation: Hepatitis C-infected organs safe for transplantation when followed by antiviral treatment
Twenty patients at Penn Medicine have been cured of the hepatitis C virus (HCV) following lifesaving kidney transplants from deceased donors who were infected with the disease, according to a study published today in Annals of Internal Medicine.

Transplantation followed by antiviral therapy cured hepatitis C
Twenty patients who received kidneys transplanted from hepatitis C virus (HCV)-infected donors experienced HCV cure, good quality of life, and excellent renal function at one year.

The Journal of Heart and Lung Transplantation: 50 years of heart transplantation progress
This month marks the 50th anniversary of the world's first human heart transplant performed at Groote Schuur Hospital in Cape Town by South African surgeon, Christiaan Barnard.

Older donor lungs should be considered for transplantation
With a scarcity of lungs available for transplantation, the use of lungs from donors older than age 60 has been shown to achieve reasonable outcomes and should be considered as a viable option, according to research published online today in The Annals of Thoracic Surgery.

Read More: Transplantation News and Transplantation Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.